Pharma & Healthcare
Global Neuromyelitis Optica Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- Apr 16, 25
- ID: 189183
- Pages: 97
- Figures: 91
- Views: 31
The global Neuromyelitis Optica Drug market size was US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
The global Neuromyelitis Optica Drug market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
By Type: (Dominant Segment vs High-Margin Innovation)
Glucocorticoids
Immunotherapies
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Acute Attack
Remission Prophylactic Treatment
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer in Europe)
- Emerging Product Trends: Glucocorticoids adoption vs. Immunotherapies premiumization
- Demand-Side Dynamics: Acute Attack growth in China vs. Remission Prophylactic Treatment potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Neuromyelitis Optica Drug market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Immunotherapies in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Remission Prophylactic Treatment in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Neuromyelitis Optica Drug value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
The global Neuromyelitis Optica Drug market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
By Type: (Dominant Segment vs High-Margin Innovation)
Glucocorticoids
Immunotherapies
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Acute Attack
Remission Prophylactic Treatment
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer in Europe)
- Emerging Product Trends: Glucocorticoids adoption vs. Immunotherapies premiumization
- Demand-Side Dynamics: Acute Attack growth in China vs. Remission Prophylactic Treatment potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Neuromyelitis Optica Drug market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Immunotherapies in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Remission Prophylactic Treatment in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Neuromyelitis Optica Drug value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2025)
2.4 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.2 Europe Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.3 China Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.4 Japan Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.6 India Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.7 Central & South America Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2020-2025)
3.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031)
3.3 Different Types Neuromyelitis Optica Drug Representative Players
4 Breakdown Data by Application
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2020-2025)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Neuromyelitis Optica Drug Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2020-2025)
5.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue
5.4 Global Neuromyelitis Optica Drug Market Concentration Analysis
5.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2024
5.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served
5.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application
5.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.1.2.2 North America Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.1.3.2 North America Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.2.2.2 Europe Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.2.3.2 Europe Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.3.2.2 China Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.3.3.2 China Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.4.2.2 Japan Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.4.3.2 Japan Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.6.2.2 India Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.6.3.2 India Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Pfizer
7.1.1 Pfizer Company Details
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Neuromyelitis Optica Drug Introduction
7.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.1.5 Pfizer Recent Development
7.2 Fresenius
7.2.1 Fresenius Company Details
7.2.2 Fresenius Business Overview
7.2.3 Fresenius Neuromyelitis Optica Drug Introduction
7.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.2.5 Fresenius Recent Development
7.3 Teva
7.3.1 Teva Company Details
7.3.2 Teva Business Overview
7.3.3 Teva Neuromyelitis Optica Drug Introduction
7.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.3.5 Teva Recent Development
7.4 Sandoz
7.4.1 Sandoz Company Details
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Neuromyelitis Optica Drug Introduction
7.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.4.5 Sandoz Recent Development
7.5 Intas
7.5.1 Intas Company Details
7.5.2 Intas Business Overview
7.5.3 Intas Neuromyelitis Optica Drug Introduction
7.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.5.5 Intas Recent Development
7.6 Gyjtrs
7.6.1 Gyjtrs Company Details
7.6.2 Gyjtrs Business Overview
7.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
7.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.6.5 Gyjtrs Recent Development
7.7 NANG KUANG
7.7.1 NANG KUANG Company Details
7.7.2 NANG KUANG Business Overview
7.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
7.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.7.5 NANG KUANG Recent Development
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Company Details
7.8.2 Tianjin Kingyork Business Overview
7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
7.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.8.5 Tianjin Kingyork Recent Development
7.9 Baxter
7.9.1 Baxter Company Details
7.9.2 Baxter Business Overview
7.9.3 Baxter Neuromyelitis Optica Drug Introduction
7.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.9.5 Baxter Recent Development
7.10 CSL
7.10.1 CSL Company Details
7.10.2 CSL Business Overview
7.10.3 CSL Neuromyelitis Optica Drug Introduction
7.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.10.5 CSL Recent Development
7.11 Grifols
7.11.1 Grifols Company Details
7.11.2 Grifols Business Overview
7.11.3 Grifols Neuromyelitis Optica Drug Introduction
7.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.11.5 Grifols Recent Development
7.12 Octapharma
7.12.1 Octapharma Company Details
7.12.2 Octapharma Business Overview
7.12.3 Octapharma Neuromyelitis Optica Drug Introduction
7.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.12.5 Octapharma Recent Development
7.13 CBOP
7.13.1 CBOP Company Details
7.13.2 CBOP Business Overview
7.13.3 CBOP Neuromyelitis Optica Drug Introduction
7.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.13.5 CBOP Recent Development
8 Neuromyelitis Optica Drug Market Dynamics
8.1 Neuromyelitis Optica Drug Industry Trends
8.2 Neuromyelitis Optica Drug Market Drivers
8.3 Neuromyelitis Optica Drug Market Challenges
8.4 Neuromyelitis Optica Drug Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2025)
2.4 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.2 Europe Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.3 China Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.4 Japan Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.6 India Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
2.5.7 Central & South America Neuromyelitis Optica Drug Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2020-2025)
3.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031)
3.3 Different Types Neuromyelitis Optica Drug Representative Players
4 Breakdown Data by Application
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2020-2025)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Neuromyelitis Optica Drug Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2020-2025)
5.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue
5.4 Global Neuromyelitis Optica Drug Market Concentration Analysis
5.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2024
5.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served
5.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application
5.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.1.2.2 North America Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.1.3.2 North America Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.2.2.2 Europe Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.2.3.2 Europe Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.3.2.2 China Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.3.3.2 China Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.4.2.2 Japan Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.4.3.2 Japan Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Neuromyelitis Optica Drug Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.6.2.2 India Neuromyelitis Optica Drug Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Neuromyelitis Optica Drug Market Size by Application (2020-2025)
6.6.3.2 India Neuromyelitis Optica Drug Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Pfizer
7.1.1 Pfizer Company Details
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Neuromyelitis Optica Drug Introduction
7.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.1.5 Pfizer Recent Development
7.2 Fresenius
7.2.1 Fresenius Company Details
7.2.2 Fresenius Business Overview
7.2.3 Fresenius Neuromyelitis Optica Drug Introduction
7.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.2.5 Fresenius Recent Development
7.3 Teva
7.3.1 Teva Company Details
7.3.2 Teva Business Overview
7.3.3 Teva Neuromyelitis Optica Drug Introduction
7.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.3.5 Teva Recent Development
7.4 Sandoz
7.4.1 Sandoz Company Details
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Neuromyelitis Optica Drug Introduction
7.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.4.5 Sandoz Recent Development
7.5 Intas
7.5.1 Intas Company Details
7.5.2 Intas Business Overview
7.5.3 Intas Neuromyelitis Optica Drug Introduction
7.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.5.5 Intas Recent Development
7.6 Gyjtrs
7.6.1 Gyjtrs Company Details
7.6.2 Gyjtrs Business Overview
7.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
7.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.6.5 Gyjtrs Recent Development
7.7 NANG KUANG
7.7.1 NANG KUANG Company Details
7.7.2 NANG KUANG Business Overview
7.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
7.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.7.5 NANG KUANG Recent Development
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Company Details
7.8.2 Tianjin Kingyork Business Overview
7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
7.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.8.5 Tianjin Kingyork Recent Development
7.9 Baxter
7.9.1 Baxter Company Details
7.9.2 Baxter Business Overview
7.9.3 Baxter Neuromyelitis Optica Drug Introduction
7.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.9.5 Baxter Recent Development
7.10 CSL
7.10.1 CSL Company Details
7.10.2 CSL Business Overview
7.10.3 CSL Neuromyelitis Optica Drug Introduction
7.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.10.5 CSL Recent Development
7.11 Grifols
7.11.1 Grifols Company Details
7.11.2 Grifols Business Overview
7.11.3 Grifols Neuromyelitis Optica Drug Introduction
7.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.11.5 Grifols Recent Development
7.12 Octapharma
7.12.1 Octapharma Company Details
7.12.2 Octapharma Business Overview
7.12.3 Octapharma Neuromyelitis Optica Drug Introduction
7.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.12.5 Octapharma Recent Development
7.13 CBOP
7.13.1 CBOP Company Details
7.13.2 CBOP Business Overview
7.13.3 CBOP Neuromyelitis Optica Drug Introduction
7.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025)
7.13.5 CBOP Recent Development
8 Neuromyelitis Optica Drug Market Dynamics
8.1 Neuromyelitis Optica Drug Industry Trends
8.2 Neuromyelitis Optica Drug Market Drivers
8.3 Neuromyelitis Optica Drug Market Challenges
8.4 Neuromyelitis Optica Drug Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Neuromyelitis Optica Drug Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Neuromyelitis Optica Drug Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Neuromyelitis Optica Drug Revenue Share by Region (2020-2025)
Table 6. Global Neuromyelitis Optica Drug Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Neuromyelitis Optica Drug Revenue Share Forecast by Region (2026-2031)
Table 8. Global Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Table 10. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Table 15. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Neuromyelitis Optica Drug Application
Table 18. Global Neuromyelitis Optica Drug Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Neuromyelitis Optica Drug Market Share by Players (2020-2025)
Table 20. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 21. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served
Table 24. Global Key Players of Neuromyelitis Optica Drug, Product and Application
Table 25. Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 29. North America Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 33. Europe Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 37. China Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 41. Japan Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 49. India Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 51. Pfizer Company Details
Table 52. Pfizer Business Overview
Table 53. Pfizer Neuromyelitis Optica Drug Product
Table 54. Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Fresenius Company Details
Table 57. Fresenius Business Overview
Table 58. Fresenius Neuromyelitis Optica Drug Product
Table 59. Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 60. Fresenius Recent Development
Table 61. Teva Company Details
Table 62. Teva Business Overview
Table 63. Teva Neuromyelitis Optica Drug Product
Table 64. Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 65. Teva Recent Development
Table 66. Sandoz Company Details
Table 67. Sandoz Business Overview
Table 68. Sandoz Neuromyelitis Optica Drug Product
Table 69. Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 70. Sandoz Recent Development
Table 71. Intas Company Details
Table 72. Intas Business Overview
Table 73. Intas Neuromyelitis Optica Drug Product
Table 74. Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 75. Intas Recent Development
Table 76. Gyjtrs Company Details
Table 77. Gyjtrs Business Overview
Table 78. Gyjtrs Neuromyelitis Optica Drug Product
Table 79. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 80. Gyjtrs Recent Development
Table 81. NANG KUANG Company Details
Table 82. NANG KUANG Business Overview
Table 83. NANG KUANG Neuromyelitis Optica Drug Product
Table 84. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 85. NANG KUANG Recent Development
Table 86. Tianjin Kingyork Company Details
Table 87. Tianjin Kingyork Business Overview
Table 88. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 89. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 90. Tianjin Kingyork Recent Development
Table 91. Baxter Company Details
Table 92. Baxter Business Overview
Table 93. Baxter Neuromyelitis Optica Drug Product
Table 94. Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 95. Baxter Recent Development
Table 96. CSL Company Details
Table 97. CSL Business Overview
Table 98. CSL Neuromyelitis Optica Drug Product
Table 99. CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 100. CSL Recent Development
Table 101. Grifols Company Details
Table 102. Grifols Business Overview
Table 103. Grifols Neuromyelitis Optica Drug Product
Table 104. Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 105. Grifols Recent Development
Table 106. Octapharma Company Details
Table 107. Octapharma Business Overview
Table 108. Octapharma Neuromyelitis Optica Drug Product
Table 109. Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 110. Octapharma Recent Development
Table 111. CBOP Company Details
Table 112. CBOP Business Overview
Table 113. CBOP Neuromyelitis Optica Drug Product
Table 114. CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 115. CBOP Recent Development
Table 116. Neuromyelitis Optica Drug Market Trends
Table 117. Neuromyelitis Optica Drug Market Drivers
Table 118. Neuromyelitis Optica Drug Market Challenges
Table 119. Neuromyelitis Optica Drug Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuromyelitis Optica Drug Product Picture
Figure 2. Global Neuromyelitis Optica Drug Market Share by Type: 2024 VS 2031
Figure 3. Glucocorticoids Features
Figure 4. Immunotherapies Features
Figure 5. Others Features
Figure 6. Global Neuromyelitis Optica Drug Market Share by Application: 2024 VS 2031
Figure 7. Acute Attack
Figure 8. Remission Prophylactic Treatment
Figure 9. Neuromyelitis Optica Drug Report Years Considered
Figure 10. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Neuromyelitis Optica Drug Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. China Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Japan Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Southeast Asia Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. India Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Central & South America Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Global Neuromyelitis Optica Drug Market Share by Players in 2024
Figure 21. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2024
Figure 23. North America Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 24. North America Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 25. Europe Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 26. Europe Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 27. China Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 28. China Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 29. Japan Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 30. Japan Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 31. Southeast Asia Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 32. Southeast Asia Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 33. India Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 34. India Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 35. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 36. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 37. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 38. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 39. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 40. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 41. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 42. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 43. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 44. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 45. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 46. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 47. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Neuromyelitis Optica Drug Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Neuromyelitis Optica Drug Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Neuromyelitis Optica Drug Revenue Share by Region (2020-2025)
Table 6. Global Neuromyelitis Optica Drug Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Neuromyelitis Optica Drug Revenue Share Forecast by Region (2026-2031)
Table 8. Global Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Table 10. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Table 15. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Neuromyelitis Optica Drug Application
Table 18. Global Neuromyelitis Optica Drug Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Neuromyelitis Optica Drug Market Share by Players (2020-2025)
Table 20. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 21. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served
Table 24. Global Key Players of Neuromyelitis Optica Drug, Product and Application
Table 25. Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 29. North America Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 33. Europe Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 37. China Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 41. Japan Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 49. India Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 51. Pfizer Company Details
Table 52. Pfizer Business Overview
Table 53. Pfizer Neuromyelitis Optica Drug Product
Table 54. Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Fresenius Company Details
Table 57. Fresenius Business Overview
Table 58. Fresenius Neuromyelitis Optica Drug Product
Table 59. Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 60. Fresenius Recent Development
Table 61. Teva Company Details
Table 62. Teva Business Overview
Table 63. Teva Neuromyelitis Optica Drug Product
Table 64. Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 65. Teva Recent Development
Table 66. Sandoz Company Details
Table 67. Sandoz Business Overview
Table 68. Sandoz Neuromyelitis Optica Drug Product
Table 69. Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 70. Sandoz Recent Development
Table 71. Intas Company Details
Table 72. Intas Business Overview
Table 73. Intas Neuromyelitis Optica Drug Product
Table 74. Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 75. Intas Recent Development
Table 76. Gyjtrs Company Details
Table 77. Gyjtrs Business Overview
Table 78. Gyjtrs Neuromyelitis Optica Drug Product
Table 79. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 80. Gyjtrs Recent Development
Table 81. NANG KUANG Company Details
Table 82. NANG KUANG Business Overview
Table 83. NANG KUANG Neuromyelitis Optica Drug Product
Table 84. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 85. NANG KUANG Recent Development
Table 86. Tianjin Kingyork Company Details
Table 87. Tianjin Kingyork Business Overview
Table 88. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 89. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 90. Tianjin Kingyork Recent Development
Table 91. Baxter Company Details
Table 92. Baxter Business Overview
Table 93. Baxter Neuromyelitis Optica Drug Product
Table 94. Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 95. Baxter Recent Development
Table 96. CSL Company Details
Table 97. CSL Business Overview
Table 98. CSL Neuromyelitis Optica Drug Product
Table 99. CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 100. CSL Recent Development
Table 101. Grifols Company Details
Table 102. Grifols Business Overview
Table 103. Grifols Neuromyelitis Optica Drug Product
Table 104. Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 105. Grifols Recent Development
Table 106. Octapharma Company Details
Table 107. Octapharma Business Overview
Table 108. Octapharma Neuromyelitis Optica Drug Product
Table 109. Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 110. Octapharma Recent Development
Table 111. CBOP Company Details
Table 112. CBOP Business Overview
Table 113. CBOP Neuromyelitis Optica Drug Product
Table 114. CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 115. CBOP Recent Development
Table 116. Neuromyelitis Optica Drug Market Trends
Table 117. Neuromyelitis Optica Drug Market Drivers
Table 118. Neuromyelitis Optica Drug Market Challenges
Table 119. Neuromyelitis Optica Drug Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuromyelitis Optica Drug Product Picture
Figure 2. Global Neuromyelitis Optica Drug Market Share by Type: 2024 VS 2031
Figure 3. Glucocorticoids Features
Figure 4. Immunotherapies Features
Figure 5. Others Features
Figure 6. Global Neuromyelitis Optica Drug Market Share by Application: 2024 VS 2031
Figure 7. Acute Attack
Figure 8. Remission Prophylactic Treatment
Figure 9. Neuromyelitis Optica Drug Report Years Considered
Figure 10. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Neuromyelitis Optica Drug Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. China Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Japan Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Southeast Asia Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. India Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Central & South America Neuromyelitis Optica Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Global Neuromyelitis Optica Drug Market Share by Players in 2024
Figure 21. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2024
Figure 23. North America Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 24. North America Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 25. Europe Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 26. Europe Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 27. China Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 28. China Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 29. Japan Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 30. Japan Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 31. Southeast Asia Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 32. Southeast Asia Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 33. India Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Figure 34. India Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 35. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 36. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 37. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 38. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 39. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 40. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 41. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 42. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 43. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 44. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 45. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 46. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 47. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Fully Automatic Vehicle Disinfection Equipment Market Research Report 2026
Mar 14, 26
Global Heat Resistant FPC Market Research Report 2026
Mar 14, 26
Global Portable Recording Stick Market Research Report 2026
Mar 14, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232